Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia

Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells

(2018) Logeswari Ponnusamy et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Epigenetic agents in combined anticancer therapy

(2018) Zdeněk Kejík et al.   Future Medicinal Chemistry

HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response

(2018) Xinfeng Liu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer

(2017) Weiwei Sheng et al.   FASEB JOURNAL

CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance

(2017) Kenneth K. W. To et al.   INVESTIGATIONAL NEW DRUGS

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

(2017) Douglas W. Sborov et al.   LEUKEMIA & LYMPHOMA

Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling

(2017) Sirichat Kaowinn et al.   CELLULAR ONCOLOGY

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit

(2017) Anna B. Halpern et al.   JAMA Oncology

Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression

(2017) Jing Yang et al.   Scientific Reports

HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia

(2016) T.-H. Lai et al.   CLINICAL CANCER RESEARCH

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

(2016) Yusuke Furukawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

(2016) Yi Liao et al.   JOURNAL OF MEDICINAL CHEMISTRY

MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification

(2016) Duk-Hwa Kwon et al.   Nature Communications

Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity

(2016) Min Song et al.   Journal of Cancer

Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease

(2015) Jonathan A.R. Gordon et al.   BONE

Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells

(2015) Sofie Steinwascher et al.   CANCER LETTERS

The interplay of histone modifications - writers that read

(2015) T. Zhang et al.   EMBO REPORTS

NEDDylation promotes endothelial dysfunction: A role for HDAC2

(2015) Deepesh Pandey et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models

(2015) Fernando F. Corrales-Medina et al.   LEUKEMIA RESEARCH

Ubiquitylation, neddylation and the DNA damage response

(2015) J. S. Brown et al.   Open Biology

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

(2014) Y. Gu et al.   BLOOD

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

(2014) Jean-Pierre Issa et al.   CANCER

Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia

(2014) H Ma et al.   ONCOGENE

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease

(2014) Shalome Bassett et al.   Nutrients

Recent progress toward epigenetic therapies: the example of mixed lineage leukemia

(2013) T. Neff et al.   BLOOD

Histone Post-translational Modifications to Target Memory-related Diseases

(2013) Barbara Monti   CURRENT PHARMACEUTICAL DESIGN

Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways

(2012) Xue-Jie Jiang et al.   CANCER LETTERS

NUB1 promotes cytoplasmic localization of p53 through cooperation of the NEDD8 and ubiquitin pathways

(2010) G Liu et al.   ONCOGENE

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy

(2008) B.D. Benites et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH